Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

Shaya Schoenoff, PA-C, reviews the efficacy and safety of Guselkumab induction therapy for moderately to severely active ulcerative colitis. Explore key findings from the Phase 2B and Phase 3 QUASAR induction studies, highlighting clinical response, endoscopic improvement, and safety outcomes compared to placebo. Learn how Guselkumab offers promising results for patients with inadequate response to conventional or advanced therapies.